These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Author: Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T.
    Journal: Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936.
    Abstract:
    An oral therapeutic regimen of famotidine, a histamine H2-receptor antagonist, was evaluated in patients with chronic renal failure who were receiving dialysis three times a week. Measurements of the half-life, bioavailability, and dialysis elimination rate were performed. The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours. The bioavailability after oral administration was 49.4% in patients with renal failure and 55.2% in control subjects. The dialysis elimination rate was stable and independent of its plasma level, with an average of 41.9%. The oral administration of famotidine (20 mg) immediately after dialysis (60 mg/week) was found optimal and safe. There were no significant side effects with this regimen.
    [Abstract] [Full Text] [Related] [New Search]